Custom mRNA vaccine takes on rare endocrine cancers

NCT ID NCT06141369

First seen Apr 15, 2026 · Last updated May 15, 2026 · Updated 8 times

Summary

This early study tests a personalized mRNA vaccine (mRNA-0523-L001) in 21 adults with advanced endocrine tumors, such as adrenal, thyroid, or pancreatic cancers, that have not responded to standard treatments. The vaccine is designed to train the immune system to attack each patient's unique tumor markers. The main goals are to check safety and measure immune responses, with early signs of tumor shrinkage also being tracked.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ruijin hospital, Shanghai Jiao-Tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.